Companies · PFE
Pfizer
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 3, 2026
Pfizer appoints Cecile Guegan as permanent CFO after interim tenure; 25-year pharma finance veteran to lead financial strategy.
Pfizer's Board unanimously elevated Cecile Guegan from interim to permanent Chief Financial Officer effective November 1, 2026, formalizing a leadership decision made in August. Guegan brings 25 years of pharmaceutical finance experience, including prior CFO roles at Wyeth (acquired by Pfizer in 2009) and successive leadership across Pfizer's Oncology, R&D, and Global Biopharmaceuticals divisions. CEO Albert Bourla emphasized her track record in optimizing financial performance and disciplined capital allocation as Pfizer aims to execute growth initiatives and deliver shareholder value in the coming decade.
Tone: neutralRevenue
$62.6B
PFE 10-K · FY 2025
Employees
75,000
Revenue FY2024
$63.6B
Founded
1942
Profile
PFE 10-K Item 1 · Feb 26, 2026Pfizer Inc. is a research-based, global biopharmaceutical company that discovers, develops, manufactures, markets, sells and distributes biopharmaceutical products worldwide. The company operates across oncology, internal medicine, vaccines, and inflammation and immunology, supplying medicines and vaccines to approximately 200 countries and territories. Its 2026 strategic priorities center on maximizing key transactions, delivering R&D milestones, investing for post-2028 growth, and scaling AI across the business.
Read filing description ↓ Collapse description ↑
Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients through improved treatment of diseases and improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room visits or hospitalizations. We seek to enhance the value of our medicines and vaccines and actively engage in dialogues about how we can best work with patients, physicians and payors to prevent and treat disease and improve outcomes. We are committed to fulfilling our purpose: Breakthroughs that change patients' lives. As a science-driven global biopharmaceutical company, we remain focused on advancing our product pipeline, supporting our marketed brands and deploying capital responsibly, with a focus on initiatives that can help contribute to our long-term revenue and future growth. We manage our commercial operations through a global structure consisting of three operating segments: Biopharma, PC1 and Pfizer Ignite. Biopharma, our innovative science-based biopharmaceutical business, is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide.
Primary products
- Eliquis
- Prevnar family
- Comirnaty
- Paxlovid
- Vyndaqel family
- Ibrance
Business segments
End markets
Geographies
Named customers
We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025. For example, Eliquis accounted for 13% of Total revenues in 2025.
“We compete with other companies that manufacture and sell products that treat or prevent diseases or indications similar to those treated or prevented by our major products. These competitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus and generic drug and biosimilar manufacturers.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, driven primarily by declines in COVID-19 product revenues, partially offset by growth in the Vyndaqel family, Eliquis, Padcev, Lorbrena, Abrysvo, and Oncology biosimilars.
The rest of PFE is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.